Science Explorer Back to mapMap

Gastric Cancer Management and Outcomes

Gastric Cancer Management and Outcomes is a research topic within Pulmonary and Respiratory Medicine. Science Explorer counts 64k research works in it since 1950. 10.1% of them reached the world's top 10% most cited for their field and year.

This cluster of papers represents a comprehensive exploration of gastric cancer, covering topics such as chemotherapy, endoscopic resection, molecular characterization, lymph node dissection, adjuvant and neoadjuvant therapy, clinical practice guidelines, metastatic gastric cancer, and survival analysis.

  • Gastric Cancer
  • Chemotherapy
  • Endoscopic Resection
  • Molecular Characterization
  • Lymph Node Dissection
  • Adjuvant Therapy
  • Clinical Practice Guidelines
  • Neoadjuvant Chemotherapy
  • Metastatic Gastric Cancer
  • Survival Analysis
Research works
64k
fractional, since 1950
In the world top 10%
6.5k
per year above
Top-10% rate
10.1%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+5%
the tick is no change
Largest producer
China
33% of the 10 largest, 2022-now
Gastric Cancer Management and Outcomes

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Gastric Cancer Management and Outcomes research?

By volume, China and the United States publish the most (3.5k and 2.2k works in 2022-now).

By volume, 2022-now

  1. 1 China 3.5k works
  2. 2 United States 2.2k works
  3. 3 Japan 1.8k works
  4. 4 South Korea 657 works
  5. 5 United Kingdom 581 works
  6. 6 Italy 482 works
  7. 7 Germany 410 works
  8. 8 India 398 works
  9. 9 Spain 302 works
  10. 10 Russia 268 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 33.0%United States: 20.7%Japan: 17.2%South Korea: 6.2%6 others listed: 22.9%33%largest
China3,526 · 33.0%United States2,213 · 20.7%Japan1,839 · 17.2%South Korea657 · 6.2%6 others listed2,440 · 22.9%

Shares of the rows listed above, not of the whole node.

Which institutions lead Gastric Cancer Management and Outcomes research?

By volume in 2022-now, Sun Yat-sen University publishes the most Gastric Cancer Management and Outcomes research, followed by Fujian Medical University and Nanjing Medical University.

Who are the leading researchers in Gastric Cancer Management and Outcomes?

The most-cited researchers publishing on Gastric Cancer Management and Outcomes include Ahmedin Jemal, Rebecca L. Siegel and Freddie Bray.

  1. 1 Ahmedin Jemal United States 761k citations
  2. 2 Rebecca L. Siegel United States 582k citations
  3. 3 Freddie Bray France 550k citations
  4. 4 Zhong Lin Wang United States 491k citations
  5. 5 Jacques Ferlay France 486k citations
  6. 6 Ali H. Mokdad United States 429k citations
  7. 7 Walter Churchill Willett United States 411k citations
  8. 8 Bert Vogelstein United States 373k citations
  9. 9 Gad A. Getz United States 364k citations
  10. 10 Hermann Brenner Germany 343k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Gastric Cancer Management and Outcomes?

The most cited paper in Gastric Cancer Management and Outcomes is "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial" (Yung‐Jue Bang, Eric Van Cutsem, Andrea Feyereislova et al., 2010), with 7,405 citations. Next come "Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer" (6,432) and "THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO‐CALLED INTESTINAL‐TYPE CARCINOMA" (6,205).

Most cited papers
#PaperReleasedCitations
1 Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Yung‐Jue Bang, Eric Van Cutsem, Andrea Feyereislova et al. · The Lancet Open access Aug 2010 7,405
2 Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer David Cunningham, William Allum, Sally Patricia Stenning et al. · New England Journal of Medicine 6 Jul 2006 6,432
3 THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO‐CALLED INTESTINAL‐TYPE CARCINOMA P Laurén · Acta Pathologica Microbiologica Scandinavica Sep 1965 6,205
4 Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer Pieter van Hagen et al. · New England Journal of Medicine Open access 31 May 2012 5,583
5 Classification and Grading of Gastritis Michael F. Dixon, Robert M. Genta, John H. Yardley et al. · The American Journal of Surgical Pathology Oct 1996 5,168
All 99 most cited papers, with filters and sorting

Where is Gastric Cancer Management and Outcomes research done?

The largest centres of Gastric Cancer Management and Outcomes research in 2022-now are Tokyo (Japan), Beijing (China), Seoul (South Korea) and Shanghai (China). Among places with at least 20 works in it, it is an unusually large share of all research in Kashiwa and Plainview.

Largest cities, 2022-now

  1. 1 TokyoJapan 458 works
  2. 2 BeijingChina 401 works
  3. 3 SeoulSouth Korea 344 works
  4. 4 ShanghaiChina 276 works
  5. 5 GuangzhouChina 236 works
  6. 6 NanjingChina 172 works
  7. 7 LondonUnited Kingdom 166 works
  8. 8 ChengduChina 156 works
  9. 9 HangzhouChina 153 works
  10. 10 OsakaJapan 150 works

Where it is the local speciality

  1. KashiwaJP · 65.6 works54×
  2. PlainviewUS · 35.6 works33×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Gastric Cancer Management and Outcomes than the world average.

See Gastric Cancer Management and Outcomes on the map

Where is the best place to study Gastric Cancer Management and Outcomes?

Among universities, judged by research, Sun Yat-sen University, Fujian Medical University and Utrecht University score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%mean 14.71%fractional works in this field (log) →share of work in the world top 10% →Utrecht UniversityFujian Medical Unive…Sun Yat-sen UniversityHumanitas University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Sun Yat-sen UniversityChina 67.713.4%5.8×145 +3.7%
2Fujian Medical UniversityChina 66.013.5%16.9×111 +13.2%
3Utrecht UniversityNetherlands 65.416.1%3.1×26 +24.2%
4Humanitas UniversityItaly 63.913.2%20.0×34 +100.8%
5Harvard UniversityUnited States 63.116.6%2.1×81 -26.7%
6Nanjing Medical UniversityChina 62.910.7%9.8×105 +38.6%
7Universidade do PortoPortugal 62.620.0%2.5×20 +36.1%
8Peking UniversityChina 62.517.4%3.8×92 -8.9%
9Sichuan UniversityChina 62.312.4%3.5×95 +13.4%
10Zhejiang UniversityChina 62.213.8%2.3×74 +20.7%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Gastric Cancer Management and Outcomes, country by country

Is Gastric Cancer Management and Outcomes research growing?

Output in 2022-2025 was 5% higher than in 2018-2021, peaking in 2024. The fastest-growing topics are Gastric Cancer Management and Outcomes.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Gastric Cancer Management and Outcomes as a percentage of every work published that year, 0.061% in 2024.

still counting0.025%0.050%0.075%Gastric Cancer Management and Outcomes0.057% in 202519801990200020102020

Fractional works of Gastric Cancer Management and Outcomes over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Gastric Cancer Management and Outcomes9.9% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Gastric Cancer Management and Outcomes. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.